ArticleMedicine2025
Tacrolimus (FK-506) levels determined by 2 different chemiluminescence immunoassay-based analytical methods: A comparative cross-sectional study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several assays have been used to monitor tacrolimus levels. Automated immunoassay systems are preferred routinely because of their simplicity and rapid turnaround times. However, variations in the measured results for the same sample by different assays necessitate the evaluation of various immunoassay systems for consistency. This study aimed to compare whole-blood tacrolimus concentrations measured using 2 different chemiluminescence analytical methods: chemiluminescent microparticle immunoassay (CMIA; Abbott Diagnostics) and chemiluminescent immunoassay (CLIA; Snibe Diagnostics). A total of 257 patients who had undergone kidney transplantation were included in this study. Whole-blood tacrolimus concentrations were measured using the MAGLUMI 800 analyzer and compared with the ARCHITECT i1000SR analyzer using correlation analysis and Bland-Altman plots. There was a strong correlation between tacrolimus concentrations measured using MAGLUMI and those measured using ARCHITECT (R = 0.916, P < .001). An intraclass correlation coefficient (ICC) value of 0.934 (CI = 0.915-0.949) indicated excellent reliability of the measurements. Comparison of samples with a routine ARCHITECT assay for tacrolimus showed a minimal bias of 0.385 ng/mL (95% CI = 4.46%-3.69%), but scattering analysis indicated that the method agreed when the tacrolimus levels were low but disagreed at high levels. Overall, the measured tacrolimus level in patient samples was higher by MAGLUMI than by ARCHITECT with a median difference of 0.17 ng/mL and a median percentage difference of 3.4% respectively. Snibe MAGLUMI is a reliable assay with excellent correlation, but a small positive bias against Abbott ARCHITECT in measuring whole-blood tacrolimus levels. This bias is most likely due to the cross-reactivity of the metabolites in the Snibe MAGLUMI platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.